





### The RESCUE BRAIN study:

A French multicenter randomized trial on neuroprotection with lower limb ischaemic per-conditioning in the acute phase of cerebral infarction (<H6)

F Pico, B Lapergue, M Ferrigno, ML Chadenat, F Bourdain, E Meseguer, M Obadia, C Hirel, DL Duong, S Deltour, C Rosso, P Aegerter, J Labreuche, A Cattenoy, D Smadja, H Hosseini, B Guillon, V Wolff, Y Samson, C Cordonnier, P Amarenco, on behalf the RESCUE BRAIN investigators



DES AFFAIRES SOCIALES ET DE LA SANTÉ









## **Speaker Disclosure**



22 - 24 May 2019 | Milan, Italy

No, nothing to disclose
Yes, please specify:

Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other (please specify)

The unique source of funding is a grant from the French Ministry of Health (PHRC).

There was no industry funding or involvement in any aspect of the trial




Les Programmes Hospitaliers de Recherche Clinique (PHRC)



#### **BACKGROUND**



- There is a need for neuroprotective agent.
- Ischemic conditioning: transient ischemia without necrosis. Endogenous mechanism



- In good quality preclinical studies in brain infarction (STAIR recommendation): positive results
  - > RIPerC effective alone. Additive effect with rTPa in a murine model of embolic stroke (Hoda et al. Stroke 2012 )
- Promising results in cardiology in myocardial infarction:
  - ▶ Botker et al. Lancet 2010, CONDI 2 Large on going trial (n= 5400). No safety issue



### **OBJECTIVE**



To evaluate if remote ischemic Per-Conditionning (RIPerC) in the unaffected

lower limb, performed in the first 6 hours of cerebral infarction reduces the

growth of the brain infarction



### **DESIGN**



- RESCUE Brain is an interventional, randomized, multicenter trial with PROBE design
- (Prospective Randomized Open, Blinded End-point)
- Source of funding: PHRC IR 2014-A00104-43 (Ministry of Health)
- Approved by the Institutional Review Board (IRB) (Ile de France XI, approval number 14023).
- ClinicalTrials.gov Identifier: NCT02189928
- Design published in Int J Stroke. 2016 Oct;11(8):938-943.
- Randomization has been stratified on the center and on IV thrombolysis.( Draft in 2013)
- Mechanical thrombectomy was allowed following IV thrombolysis (Draft in 2013)
- Interim analysis at half recruitment ( n=102 patients)



### **DESIGN**








#### Patients in the intervention group:

- Cuff is placed in the thigh (unaffected side)
- Target inflation BP = 110 mm Hg above syst BP
- Electronic tourniquet is program to deliver
- 4 cycles of 5 min inflation
- With 4 cycles of deflation in between
- Total duration = 40 minutes





H 24 NIHSS D 7 : NIHSS

• M3: Rankin

DWI H24 (H24-H36)

#### Patients in the Control group:

The cuff is placed but no inflation

#### Main inclusion criteria:

- patients with carotid BI
- proven by brain MRI < H6</li>
- NIHSS score: 5 and 25.

#### **Primary Endpoint:**


- DWI volume (cc) H24 Baseline (<H6)
- Central lab for lecture of brain MRI, blinded to clinical data, date of MRI.



### **RESCUE BRAIN Network**




11 French stroke centers (7 in Paris area)





#### **FLOW CHART**







### **BASELINE CHARACTERISTICS**



Baseline demographics and medical history	Overall (N=188)	rIPerC (N=93)	Control (N=95)
Age, years, mean (SD)	67.2 (15.7)	67.8 (15.1)	66.7 (16.4)
Men	98/188 (52.1)	45/93 (48.4)	53/95 (55.8)
BMI, Kg/m², mean (SD)¹	26.3 (5.4)	26.2 (5.1)	26.5 (5.8)
Medical history			
Hypertension	98/188 (52.1)	48/93 (51.6)	50/95 (52.6)
Diabetes	30/188 (16.0)	12/93 (12.9)	18/95 (19.0)
Hypercholesterolemia	72/188 (38.3)	32/93 (34.4)	40/95 (42.1)
Current smoking	30/179 (16.8)	14/88 (15.9)	16/91 (17.6)
Coronary artery disease	24/188 (12.8)	12/93 (12.9)	12/95 (12.6)
Previous stroke or TIA	24/188 (12.8)	11/93 (11.8)	13/95 (13.7)
Previous atrial fibrillation	32/188 (17.0)	18/93 (19.4)	14/95 (14.7)



### **BASELINE CHARACTERISTICS**



Current stroke event	Overall (N=188)	rIPerC (N=93)	Control (N=95)
Admission NIHSS score, median (IQR)	10 (6 to 16)	9 (6 to 15)	10 (7 to 17)
Onset to baseline MRI time, min, median (IQR)	104 (82 to 145)	105 (81 to 147)	103 (83 to 142)
Occlusion at MRI			
None	59/188 (31.4)	30/93 (32.3)	29/95 (30.5)
MCA	94/188 (50.0)	45/93 (48.4)	49/95 (51.6)
Cervical ICA	6/188 (3.2)	6/93 (6.4)	0/95 (0.0)
Carotid T	11/188 (5.9)	6/93 (6.4)	5/95 (5.3)
Others	18/188 (9.6)	6/93 (6.4)	12/95 (12.6)
Baseline brain infarct volume, cm³, median (IQR)³	11.4 (3.6 to 35.8)	10.2 (3.4 to 38.7)	12.2 (3.7 to 32.3)



### **BASELINE CHARACTERISTICS**



Treatments of current stroke event	Overall (N=188)	rIPerC (N=93)	Control (N=95)
IV thrombolysis	164/188 (87.2)	82/93 (88.2)	82/95 (86.3)
Onset to IV thrombolysis time, min, median (IQR)	149 (111 to 179)	154 (111 to 186)	145 (112 to 175)
Endovascular treatment	64/188 (34.0)	30/93 (32.3)	34/95 (35.8)
Onset to groin puncture time, min, median (IQR)	187 (145 to 247)	187 (130 to 250)	182 (150 to 245)
Onset to rIPerC time, min, median (IQR)	-	222 (176 to 275)	-

- 87 % of patients have been treated by I.V. thrombolysis with a median time of 2h30
- 34% patients have been treated by endovascular treatment with a median time of 3 h10
- Concerning rIPerC the median time between stroke onset and cuff inflation was 3 h40.



### **PRIMARY ENDPOINT**



Brain MRI Volume	rlPerC (n=93)	Control (n=95)	P-Value
ITT analysis			
Baseline, median (IQR)	9.3 (3.4 to 38.3)	12.2 (3.7 to 32.3)	
24-hours, median (IQR)	13.0 (3.2 to 54.7)	18.8 (4.9 to 66.7)	
Mean (log ) change (95%CI)	0.30 (0.11 to 0.48) <sup>2</sup>	0.37 (0.19 to 0.55)	0.57
PP analysis			
Baseline, median (IQR)	9.1 (3.3 to 37.9)	12.1 (3.8 to 32.0)	
24-hours, median (IQR)	13.0 (3.6 to 45.4)	18.5 (4.8 to 60.0)	
Mean (log <sub>e</sub> ) change (95%CI)	0.30 (0.12 to 0.49) <sup>2</sup>	0.33 (0.14 to 0.51)	0.86



90-day mRs 0-1

90-day mRs, median (IQR)



0.26

0.35

SECON	DARY ENDP	RY ENDPOINT		
	rIPerC (n=93)	Control (n=95)	P-Value	
% change in BI volume at 24-hours, median (IQR) <sup>1</sup>	36.5 (-7.3 to 98.1)	34.1 (-11.0 to 106.4)	0.80	
Change NIHSS score at 24-hours				
Baseline, median (IQR)	9 (6 to 15)	10 (7 to 17)		
24-hours, median (IQR)	5 (2 to 9)	7 (2 to 12)		
Mean (log <sub>e</sub> ) change (95%CI)	-0.59 (-0.75 to -0.43)	-0.51 (-0.67 to -0.35)	0.48	

Baseline, median (IQR)	9 (6 to 15)	10 (7 to 17)	
24-hours, median (IQR)	5 (2 to 9)	7 (2 to 12)	
Mean (log <sub>e</sub> ) change (95%CI)	-0.59 (-0.75 to -0.43)	-0.51 (-0.67 to -0.35)	0.48
Successful recanalization in IV-treated patients	62 (75.6)	65 (79.5)	0.65
90-day Bathel ≥95	61 (67.2)	56 (61.3)	0.41

44 (48.6)

2 (1 to 3)

37 (40.3)

2 (1 to 3)



### **SAFETY**



	With at least one cycle of deflation/inflation		
	Yes (n=94)	No (n=94)	P-Value
Symptomatic Intracerebral hemorrhage	4/88 (4.6)	4/88 (4.6)	0.97
90-day All-cause mortality, n ( %)	14 (15.8)	10 (10.4)	0.45
Pain (VAS) during per-conditioning ischemic procedure			
>0	41/78 (52.6)	-	-
Median (IQR)	6 (3 to 7)	-	-
(Data reported for only for patients with VAS>0)			

#### **PerCID** related event:

- No acute limb ischemia
- No deep venous thrombosis



### **DISCUSSION**



- Previous RCT on rlPerC in acute Stroke (KD Hougaard et al. Stroke 2014) G Andersen, Aarhus University Denmark
  - Prehospital setting: 64 and 57 patients analyzed with post rIPerC MRI (DWI and PWI)
  - Low NIHSS = 4 and small volume 1 cc.
  - Neutral but post hoc voxel analyses suggest rIPerC can be beneficial
- 5 on going trial on rIPerC in AIS: 2 in Prehospital and 3 with multiple cycle of per CID

Name	Country (PI)	n	Patients	Intervention	Intervention	Outcomes
RESIST	Denmark (R A Blauenfeldt)	1500	AIS HIC	<ul><li>PreHosp</li><li>Non paretic Arm</li></ul>	<ul><li>InHosp H6</li><li>D1-D7 = *2/d</li></ul>	mRS 2022
REMOTE-CAT	Spain,Catalonia (F Purroy Garcia )	575	AIS	<ul><li>PreHosp &lt; H8</li><li>Non paretic Arm</li></ul>	• Once	mRS 2022
RE CAST-2	United Kingdom (T England)	120	AIS	<ul><li>In Hosp</li><li>Non paretic arm</li></ul>	• D1-D4*2/d	Feasibility 2018
TRIPCAIS	China (A Jiaqi)	120	AIS rTPA	<ul><li>In Hosp</li><li>Non paretic arm</li></ul>	<ul> <li>Once after IV thrombolysis</li> </ul>	2020
REPOST	Netherlands (T Landman)	200	AIS	<ul><li>In Hosp</li><li>Non paretic arm</li></ul>	Twile daily	Infarct size



### **CONCLUSION**



**RESCUE BRAIN** is a neutral RCT evaluating

in hospital remote ischemic per conditioning at lower limb

within the 6 first hours of proven ischemic stroke

on top on IV thrombolysis and mechanical thrombectomy





**₹**ESCUE

# Acknowledgements

#### Patients and their families

#### Center (number of patients included)

VERSAILLES HOSPITAL (n=48) Pr PICO, Dr CHADENAT, Dr DUONG et al.

FOCH HOSPITAL (n=42) Dr LAPERGUE, Dr BOURDAIN, Dr CONSOLI, et al.

LILLE HOSPITAL (n=28) Pr CORDONNIER, Dr FERRIGNO et al.

BICHAT AP-HP (n=18) Pr AMARENCO, Dr MESEGUER et al.

SALPETRIERE AP HP (n=15) Pr SAMSON, Dr ROSSO, Dr DELTOUR et al.

CH SUD FRANCILIEN (n=15) Pr SMADJA, Dr CHAUSSON, Dr AGHASARYAN et al.

ROTSCHILD HOSPITAL (n=11) Dr OBADIA, Dr PIOTIN, Dr FISSELIER et al.

MONDOR APHP (n=5) Pr HOSSEINI, Dr MAJHAI et al.

NANTES HOSPITAL (n=3) Dr GUILLON, Dr SEVIN et al.

STRASBOURG HOSPITAL(n=3) Pr WOLFF et al.

RENNES HOSPITAL (n=0) Dr RONZIERE etal.

Les Programmes Hospitaliers de Recherche Clinique (PHRC)



#### **DSMB**:

- Pr ALAMOWITCH ( Paris)
- Pr OLIVOT (Toulouse)
- Ms COZIC (Paris )

#### **BRAIN MRI Lecture group:**

- Dr C ROSSO (BRAIN AND SPINE INSTITUTE)
- Dr C HIREL (VERSAILLES HOSPITAL)

#### **VERSAILLES CLINICAL RESEARCH UNIT:**

- Ms MORISSET
- Ms CATTENOY, Ms ROUX
- Ms LEFEVRE, Mr TURBE

#### PARIS OUEST CLINICAL RESEARCH UNIT

- Pr AEGERTER ( Methodologist)
- Ms AZERAD (Data Manager)
- Ms NKAM (Statistician)

#### LILLE BIOSTATISTIC DEPARTMENT

- Pr DUHAMFL
- Mr LABREUCHE( Statistician)